Technical Analysis for SGEN - Seattle Genetics, Inc.

Grade Last Price % Change Price Change
grade C 56.19 -1.52% -0.87
SGEN closed down 1.52 percent on Tuesday, November 20, 2018, on approximately normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Strong Down Down Down
See historical SGEN trend table...

Date Alert Name Type % Chg
Nov 19 NR7 Range Contraction -1.52%
Nov 19 Inside Day Range Contraction -1.52%
Nov 16 Pocket Pivot Bullish Swing Setup -2.16%
Nov 16 Wide Bands Range Expansion -2.16%
Nov 15 MACD Bullish Signal Line Cross Bullish 3.31%
Nov 15 Pocket Pivot Bullish Swing Setup 3.31%
Nov 15 Volume Surge Other 3.31%
Nov 15 Wide Bands Range Expansion 3.31%
Nov 14 MACD Bearish Signal Line Cross Bearish 5.86%
Nov 14 Wide Bands Range Expansion 5.86%

Older signals for SGEN ...

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Seattle Genetics, Inc., a biotechnology company, focuses on the development and commercialization of monoclonal antibody-based therapies for cancer. Its product candidate, ADCETRIS, has accelerated approval form the U.S. Food and Drug Administration for the treatment of patients with Hodgkin lymphoma after failure of autologous stem cell transplant (ASCT) or after failure of at least two prior multi-agent chemotherapy regimens; and for the treatment of patients with systemic anaplastic large cell lymphoma (sALCL) after failure of at least one prior multi-agent chemotherapy regimen. The company's ADCETRIS is in Phase III trial for patients with Hodgkin lymphoma at high risk of relapse following ASCT; Phase II retreatment trial for patients with Hodgkin lymphoma or sALCL; Phase II trial for patients with relapsed or refractory CD30-positive non-Hodgkin lymphomas; Phase II CD30-screening and treatment trial for patients with CD30-positive non-lymphoma malignancies; Phase I safety trial in combination with Adriamycin, vinblastine, bleomycin, and dacarbazine, or in combination with AVD for front-line treatment of patients with Hodgkin lymphoma; and Phase I safety trial for the treatment of patients with mature T-cell lymphomas, including sALCL. Its product pipeline also comprises SGN-75, which completed Phase I trial for relapsed or refractory non-Hodgkin lymphoma and renal cell carcinoma; ASG-5ME that is in Phase I trial for treating metastatic pancreatic cancer and castration-resistant prostate cancer; ASG-22ME, which is in Phase I trial for treatment of Nectin-4 -positive solid tumors; and SGN-CD19A for CD19-positive hematologic malignancies. The company has a strategic collaboration with Oxford BioTherapeutics Ltd. to jointly discover antibody-drug conjugates (ADC) for the treatment of cancer. Seattle Genetics, Inc. was founded in 1997 and is headquartered in Bothell, Washington.
Is SGEN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicator Value
52 Week High 84.37
52 Week Low 47.75
Average Volume 1,207,076
200-Day Moving Average 63.4644
50-Day Moving Average 68.809
20-Day Moving Average 57.3495
10-Day Moving Average 56.754
Average True Range 3.1167
ADX 35.45
+DI 20.483
-DI 34.7529
Chandelier Exit (Long, 3 ATRs ) 62.2799
Chandelier Exit (Short, 3 ATRs ) 60.0601
Upper Bollinger Band 63.5426
Lower Bollinger Band 51.1564
Percent B (%b) 0.41
BandWidth 21.597747
MACD Line -3.6367
MACD Signal Line -4.1598
MACD Histogram 0.5231
Fundamentals Value
Market Cap 8.03 Billion
Num Shares 143 Million
EPS -1.43
Price-to-Earnings (P/E) Ratio -39.29
Price-to-Sales 20.40
Price-to-Book 15.26
PEG Ratio -0.08
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 59.17
Resistance 3 (R3) 59.19 58.22 58.67
Resistance 2 (R2) 58.22 57.47 58.21 58.51
Resistance 1 (R1) 57.21 57.00 57.72 57.18 58.34
Pivot Point 56.24 56.24 56.49 56.23 56.24
Support 1 (S1) 55.22 55.48 55.73 55.20 54.04
Support 2 (S2) 54.25 55.01 54.24 53.87
Support 3 (S3) 53.24 54.25 53.71
Support 4 (S4) 53.21